Literature DB >> 21284668

Models and mechanisms of fibrosis resolution.

Victoria K Snowdon1, Jonathan A Fallowfield.   

Abstract

Liver fibrosis and its end stage, cirrhosis, represent the final common pathway of virtually all chronic liver diseases. As our understanding of the pathogenesis of liver fibrosis has progressed, it has become evident that the liver provides a useful generic model of inflammation and repair, demonstrating interplay between the epithelial, inflammatory, myofibroblast and extracellular matrix components of the mammalian wound healing response. In this review, the paradigm that liver fibrosis is a potentially reversible process-demonstrating both fibrosis (scarring) and resolution with remodeling and restitution of normal or near-normal tissue architecture-will be explored. The remarkable progress in unraveling the complexities of liver fibrosis has been due to developments in technologies including the isolation of discrete liver cell populations which have facilitated studies of their behavior in tissue culture and in vivo. More recently, animal models that mimic chronic liver diseases have been established. These models are tractable and can be applied in gene knockout and transgenic mice. This article will highlight recent studies that reveal key mechanisms mediating the regression of liver fibrosis which have derived from the use of such complementary animal and human model systems and describe how our greater understanding of this dynamic process is likely to inform the development of directed and effective anti-fibrotic approaches.
Copyright © 2011 by the Research Society on Alcoholism.

Entities:  

Mesh:

Year:  2011        PMID: 21284668     DOI: 10.1111/j.1530-0277.2010.01400.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  11 in total

1.  Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations.

Authors:  Meng Yin; Kevin J Glaser; Jayant A Talwalkar; Jun Chen; Armando Manduca; Richard L Ehman
Journal:  Radiology       Date:  2015-07-08       Impact factor: 11.105

2.  Gene expression profiles reveal molecular mechanisms involved in the progression and resolution of bleomycin-induced lung fibrosis.

Authors:  Sandra Cabrera; Moises Selman; Alfredo Lonzano-Bolaños; Kazuhisa Konishi; Thomas J Richards; Naftali Kaminski; Annie Pardo
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-01       Impact factor: 5.464

3.  Establishment of a hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol.

Authors:  Lei Wang; Fu-Liang He; Fu-Quan Liu; Zhen-Dong Yue; Hong-Wei Zhao
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

Review 4.  Allostasis in nonalcoholic fatty liver disease: implications for risk assessment.

Authors:  György Baffy
Journal:  Dig Dis Sci       Date:  2012-08-11       Impact factor: 3.199

5.  Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis.

Authors:  Tingfen Li; Yongmin Yan; Bingying Wang; Hui Qian; Xu Zhang; Li Shen; Mei Wang; Ying Zhou; Wei Zhu; Wei Li; Wenrong Xu
Journal:  Stem Cells Dev       Date:  2012-11-07       Impact factor: 3.272

6.  Bone marrow-derived mesenchymal stem cells effectively regenerate fibrotic liver in bile duct ligation rat model.

Authors:  Hoda E Mohamed; Sahar E Elswefy; Laila A Rashed; Nahla N Younis; Mohamed A Shaheen; Amal M H Ghanim
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-24

7.  Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver.

Authors:  S Tamir Rashid; Jonathan D Humphries; Adam Byron; Ameet Dhar; Janet A Askari; Julian N Selley; David Knight; Robert D Goldin; Mark Thursz; Martin J Humphries
Journal:  J Proteome Res       Date:  2012-06-28       Impact factor: 4.466

Review 8.  Mesenchymal stem cell therapy for liver fibrosis.

Authors:  Young Woo Eom; Kwang Yong Shim; Soon Koo Baik
Journal:  Korean J Intern Med       Date:  2015-08-27       Impact factor: 2.884

Review 9.  Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis.

Authors:  Kyeong-Ah Kwak; Hyun-Jae Cho; Jin-Young Yang; Young-Seok Park
Journal:  Can J Gastroenterol Hepatol       Date:  2018-01-29

10.  Ligand Activation of PPARγ by Ligustrazine Suppresses Pericyte Functions of Hepatic Stellate Cells via SMRT-Mediated Transrepression of HIF-1α.

Authors:  Feng Zhang; Shuai Lu; Jianlin He; Huanhuan Jin; Feixia Wang; Li Wu; Jiangjuan Shao; Anping Chen; Shizhong Zheng
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.